RxDoctor Payments Data

Pratik Patel, MD

Family Medicine · Spring, TXNPI 1235572686

Payments from drug & device makers

$749in general payments, 2019–2025

Across 15 payments — averaging $49.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$301
  • AstraZeneca$128
  • Amarin Pharma, Inc.$120
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$110
  • Lilly USA, LLC$52
  • Dexcom, Inc.$23
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$749100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$749 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$150,294
Medicare patients
428
Services billed
2,653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$68,267
JardianceEmpagliflozin22$28,353
TrulicityDulaglutide11$25,133
MounjaroTirzepatide15$19,234
FarxigaDapagliflozin Propanediol11$17,808
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$12,485
Aripiprazole18$8,340
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,071
Wixela InhubFluticasone Propion/Salmeterol12$3,589
Rosuvastatin Calcium236$3,115
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$2,644
Atorvastatin Calcium210$2,274
Levothyroxine Sodium169$1,997
Albuterol Sulfate HfaAlbuterol Sulfate76$1,637
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen73$1,529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$68,26760 claims
Lilly USA, LLCTrulicity, Mounjaro$52$44,36726 claims
AstraZenecaFarxiga$128$17,80811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Spring

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →